Retour sur lavenir.net
   ACKERMANS V.HAAREN 284.800 € (-0,77 %)     AB INBEV 74.680 € (+1,22 %)     ARGENX SE 784.400 € (+0,33 %)     UMICORE 20.820 € (-2,25 %)     VASTNED 29.750 € (+0,34 %)     KBC ANCORA 80.900 € (+0,62 %)     IBA 16.760 € (+0,60 %)     KBC 117.250 € (-0,51 %)     ELIA GROUP 138.500 € (-0,86 %)     WDP 22.520 € (+1,08 %)     HOME INVEST BE. 19.300 € (-0,21 %)     AZELIS GROUP 9.910 € (-0,10 %)     WHAT'S COOKING GP 144.500 € (0,00 %)     EVS 27.700 € (-0,72 %)     SYENSQO 66.800 € (-0,30 %)     BPOST 1.552 € (-0,51 %)     TITAN S.A. 52.500 € (-1,50 %)     MONTEA 67.200 € (+1,66 %)     MELEXIS 76.400 € (-3,41 %)     GIMV 45.150 € (+2,03 %)     SHURGARD 25.750 € (+0,98 %)     CENERGY 23.300 € (-3,80 %)     KINEPOLIS GROUP 36.500 € (+2,38 %)     JENSEN-GROUP 84.200 € (+1,45 %)     ORANGE BELGIUM 21.500 € (0,00 %)     SIPEF 92.900 € (+0,32 %)     CIE BOIS SAUVAGE 302.000 € (0,00 %)     FLUXYS BELGIUM D 19.500 € (+0,26 %)     RETAIL ESTATES 70.100 € (+0,43 %)     ATENOR 1.690 € (-3,43 %)     FAGRON 23.800 € (-0,63 %)     ACCENTIS 0.026 € (-1,89 %)     BEKAERT 39.500 € (-1,86 %)     XIOR 26.700 € (+1,14 %)     WERELDHAVE BELGIUM 52.800 € (+0,76 %)     PROXIMUS 6.085 € (-0,33 %)     D'IETEREN GROUP 170.500 € (-1,73 %)     TINC 11.380 € (0,00 %)     SOFINA 220.200 € (+0,46 %)     ONWARD MEDICAL 2.640 € (+0,96 %)     ECONOCOM GROUP 1.515 € (+1,68 %)     GBL 78.950 € (-0,19 %)     RECTICEL 10.740 € (-1,10 %)     NYXOAH 1.530 € (+3,66 %)     AGEAS 69.750 € (+0,50 %)     AGFA-GEVAERT 0.423 € (-1,40 %)     COFINIMMO 84.500 € (+1,62 %)     CARE PROPERTY INV. 12.600 € (+0,48 %)     LOTUS BAKERIES 11 520.000 € (+0,88 %)     VGP 84.300 € (0,00 %)     VIOHALCO 19.320 € (-0,92 %)     BIOTALYS 3.120 € (-1,58 %)     ONTEX GROUP 2.525 € (+0,20 %)     TUBIZE-FIN 225.400 € (+2,55 %)     VAN DE VELDE 30.200 € (0,00 %)     CAMPINE 218.000 € (+1,87 %)     CMB.TECH 12.500 € (-4,87 %)     DECEUNINCK 2.220 € (0,00 %)     CELYAD ONCOLOGY 0.251 € (+0,40 %)     BREDERODE 104.600 € (+1,36 %)  
   NANOBIOTIX 31.080 € (+3,74 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     TOTALENERGIES 68.360 € (-1,31 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     ADYEN 824.900 € (+0,37 %)     EXAIL TECHNOLOGIES 116.700 € (+25,28 %)     SHELL PLC 33.700 € (-1,00 %)     CAPGEMINI 89.680 € (+1,33 %)     BUREAU VERITAS 26.120 € (+0,66 %)     HERMES INTL 1 626.000 € (+0,77 %)     PHILIPS KON 23.890 € (-0,17 %)     SANOFI 75.070 € (+1,78 %)     ASML HOLDING 1 578.200 € (-0,99 %)     BOLLORE 4.100 € (+0,15 %)     VEOLIA ENVIRON. 36.230 € (+0,22 %)     SMCP 5.015 € (+0,30 %)     FLOW TRADERS 25.580 € (-0,93 %)     ASM INTERNATIONAL 948.000 € (-4,34 %)     AYVENS 11.460 € (-0,87 %)     CSG 12.682 € (+2,69 %)     BE SEMICONDUCTOR 282.700 € (-2,21 %)     SCOR SE 31.980 € (+0,50 %)     STMICROELECTRONICS 62.580 € (-3,81 %)     ESSILORLUXOTTICA 168.650 € (+1,54 %)     CRCAM TOURAINE CCI 138.500 € (-0,93 %)     LISI 66.100 € (-0,15 %)     LVMH 495.750 € (+0,27 %)     BOUYGUES 49.750 € (-0,78 %)     DSM FIRMENICH AG 79.980 € (-0,65 %)     NEXANS 141.100 € (-3,75 %)     STELLANTIS NV 5.024 € (-1,95 %)     THALES 216.500 € (-0,87 %)     UMG 18.355 € (+0,71 %)     NN GROUP 76.320 € (-0,29 %)     AHOLD DEL 35.430 € (+0,85 %)     2CRSI 27.520 € (+8,01 %)     SODEXO 51.250 € (-0,10 %)     SOITEC 114.350 € (+1,87 %)     TKH GROUP 43.620 € (+1,73 %)     LNA SANTE 34.000 € (+3,03 %)     OVH 13.600 € (+1,49 %)     BAM GROEP KON 12.550 € (-1,18 %)     AMG 32.900 € (-1,56 %)     EUROFINS SCIENT. 68.960 € (+1,00 %)     CEGEDIM 11.040 € (-1,43 %)     AALBERTS NV 38.980 € (-1,66 %)     DANONE 72.120 € (+3,06 %)     ALSTOM 15.380 € (-1,94 %)     REXEL 36.860 € (-1,18 %)     RELX 27.440 € (-0,29 %)     HAFFNER ENERGY 0.217 € (-2,25 %)     ERAMET 45.160 € (-1,40 %)     SAINT GOBAIN 80.600 € (-1,42 %)     BNP PARIBAS ACT.A 101.120 € (-1,83 %)     RUBIS 31.540 € (+0,64 %)     JCDECAUX 19.050 € (+1,33 %)     PERNOD RICARD 65.960 € (-0,06 %)     SAVENCIA 66.600 € (0,00 %)     AIRBUS 191.900 € (-1,63 %)     ALTEN 53.400 € (+1,81 %)  
News Réglementées
19/06/2026 11:30

Ottobock sells its Human Mobility wheelchair business

EQS-News: Ottobock SE & Co. KGaA / Key word(s): Disposal/Strategic Company Decision
Ottobock sells its Human Mobility wheelchair business

19.06.2026 / 11:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Ottobock sells its Human Mobility wheelchair business

Ottobock sharpens its strategic focus on its core business / DHCare invests in the expansion of its European business

Duderstadt, June 19, 2026
 

Publicly listed global MedTech company Ottobock SE & Co. KGaA signed an agreement on June 19, 2026 to sell its Human Mobility business unit to the international medical technology company DHCare. The transaction is expected to close in H2/2026.

With the sale, Ottobock is consistently continuing its strategic focus on its core business. In the future, the company will concentrate even more strongly on the areas where it sees the greatest growth potential, particularly prosthetics and neuro-orthotics.

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA, said: “By selling our wheelchair business, we are sharpening our strategic focus on our core business. At the same time, with DHCare we have found the right investor for Human Mobility. The team has built a technologically leading business with strong clinical credibility and close customer relationships. We are convinced that Human Mobility has the best opportunities for growth in its new environment.”

A strategic step with a clear perspective

With DHCare, Human Mobility gains a new owner with a broad European footprint and a complementary portfolio. Human Mobility contributes, above all, its strong position in the DACH region and its expertise in complex powered wheelchairs.

Graham Ewart, CEO of DHCare, said: “This acquisition is an important milestone for DHCare. It is our first under the new ownership structure and our first as a combined platform. With Ottobock Human Mobility, we are taking another significant step in expanding our position as a leading provider of mobility solutions in Europe — with high-quality, clinically proven solutions as well as technical support and high-level after-sales service.”

Secured transition for employees and market partners

As part of the transaction, the German Human Mobility companies as well as Dutch pediatric wheelchair specialist veldink4Kids will transfer in full to the new group.

For users, payers, service providers and specialist retailers alike, Ottobock will remain a reliable partner until the transaction is completed.

Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA, said: “By divesting this non-core business area, we are continuing to sharpen our focus on expanding high-growth and highly innovative businesses. At the same time, it is important to us to ensure an orderly and reliable transition for the employees and locations affected, as well as for customers and partners. In DHCare, we have found a partner that wants to further develop Human Mobility within a strong European mobility environment.”

Note: In connection with this transaction, the French subsidiaries of both groups have entered into exclusive negotiations for the sale of the French Human Mobility business, and the relevant employee information and consultation processes will be initiated shortly.
 

Media Contact:

Ottobock SE & Co. KGaA
Merle Florstedt
Head of Corporate Communications
Mobile +49 151 441 616 25
Merle.florstedt@ottobock.de 

 

Investor Relations Contact:

Ottobock SE & Co. KGaA
Julia Hartmann
VP Investor Relations
Mobile: +49 151 556 848 07
Julia.Hartmann@ottobock.de

 

About Ottobock

Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988. 

 

About DHCare

DHCare is a global medical device company that supports efforts to move health forward by delivering innovative and leading solutions for individuals whose lives are impacted by reduced movement.

We strive to constantly support our healthcare partners, and the people whose healthcare needs they serve, working to keep improving the vital connections between movement and health, enabling accelerated recovery and healthy independence in daily living.

 



19.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:Ottobock SE & Co. KGaA
Max-Näder-Straße 15
37115 Duderstadt
Germany
Phone:+49 5527 848 - 0
E-mail:info@ottobock.com
Internet:https://corporate.ottobock.com
ISIN:DE000BCK2223
WKN:BCK222
Indices:SDAX
Listed:Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange
EQS News ID:2349470

 
End of NewsEQS News Service

2349470  19.06.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière